|

A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea

RECRUITINGSponsored by Takeda
Actively Recruiting
SponsorTakeda
Started2025-09-29
Est. completion2029-09-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07035886

Summary

The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age greater than or equal to (\>=)18 years.
* Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea.
* Participant voluntarily consent to participate in the study.

Exclusion criteria:

* Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label.
* Participants actively participating in other interventional clinical trial(s) on mCRC treatments.
* Pregnant or breastfeeding women.

Conditions2

CancerColorectal Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.